Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $85,578.12 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,732 shares of the business’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $49.41, for a total transaction of $85,578.12. Following the completion of the sale, the chief executive officer now owns 505,846 shares in the company, valued at $24,993,850.86. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Twist Bioscience Stock Performance

TWST stock opened at $47.83 on Wednesday. The company’s 50 day simple moving average is $42.67 and its 200-day simple moving average is $37.99. Twist Bioscience Co. has a 52-week low of $14.42 and a 52-week high of $55.26.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. During the same period in the previous year, the firm posted ($1.06) earnings per share. The firm’s revenue was up 25.1% on a year-over-year basis. On average, research analysts anticipate that Twist Bioscience Co. will post -3.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on TWST. Barclays boosted their target price on shares of Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Guggenheim began coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 target price on the stock. TD Cowen boosted their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. Evercore ISI boosted their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Finally, Robert W. Baird boosted their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Twist Bioscience presently has a consensus rating of “Buy” and a consensus price target of $46.63.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Federated Hermes Inc. purchased a new position in Twist Bioscience during the third quarter valued at approximately $29,000. EdgeRock Capital LLC bought a new stake in Twist Bioscience in the fourth quarter worth approximately $30,000. Headlands Technologies LLC bought a new stake in Twist Bioscience in the first quarter worth approximately $124,000. International Assets Investment Management LLC grew its position in Twist Bioscience by 3,519.8% in the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after acquiring an additional 3,907 shares in the last quarter. Finally, Brown Advisory Inc. bought a new stake in Twist Bioscience in the fourth quarter worth approximately $225,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.